Recent developments in the management of severe asthma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Recent developments in the management of severe asthma. / Meteran, Howraman; Tønnesen, Louise Lindhardt; Sivapalan, Pradeesh; Ingebrigtsen, Truls Sylvan; Jensen, Jens Ulrik Stæhr.

In: Breathe, Vol. 18, No. 1, 210178, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Meteran, H, Tønnesen, LL, Sivapalan, P, Ingebrigtsen, TS & Jensen, JUS 2022, 'Recent developments in the management of severe asthma', Breathe, vol. 18, no. 1, 210178. https://doi.org/10.1183/20734735.0178-2021

APA

Meteran, H., Tønnesen, L. L., Sivapalan, P., Ingebrigtsen, T. S., & Jensen, J. U. S. (2022). Recent developments in the management of severe asthma. Breathe, 18(1), [210178]. https://doi.org/10.1183/20734735.0178-2021

Vancouver

Meteran H, Tønnesen LL, Sivapalan P, Ingebrigtsen TS, Jensen JUS. Recent developments in the management of severe asthma. Breathe. 2022;18(1). 210178. https://doi.org/10.1183/20734735.0178-2021

Author

Meteran, Howraman ; Tønnesen, Louise Lindhardt ; Sivapalan, Pradeesh ; Ingebrigtsen, Truls Sylvan ; Jensen, Jens Ulrik Stæhr. / Recent developments in the management of severe asthma. In: Breathe. 2022 ; Vol. 18, No. 1.

Bibtex

@article{a8491898e24e40ba971145fb340bf91a,
title = "Recent developments in the management of severe asthma",
abstract = "Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation.",
author = "Howraman Meteran and T{\o}nnesen, {Louise Lindhardt} and Pradeesh Sivapalan and Ingebrigtsen, {Truls Sylvan} and Jensen, {Jens Ulrik St{\ae}hr}",
year = "2022",
doi = "10.1183/20734735.0178-2021",
language = "English",
volume = "18",
journal = "Breathe",
issn = "1810-6838",
publisher = "European Respiratory Society",
number = "1",

}

RIS

TY - JOUR

T1 - Recent developments in the management of severe asthma

AU - Meteran, Howraman

AU - Tønnesen, Louise Lindhardt

AU - Sivapalan, Pradeesh

AU - Ingebrigtsen, Truls Sylvan

AU - Jensen, Jens Ulrik Stæhr

PY - 2022

Y1 - 2022

N2 - Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation.

AB - Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation.

U2 - 10.1183/20734735.0178-2021

DO - 10.1183/20734735.0178-2021

M3 - Journal article

C2 - 36338257

AN - SCOPUS:85130756860

VL - 18

JO - Breathe

JF - Breathe

SN - 1810-6838

IS - 1

M1 - 210178

ER -

ID: 327686931